Results
|
|
1.
|
Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. MedStar authors:
Year: 2019
Citation: - The Lancet Diabetes & Endocrinology. 7(8):596-605, 2019 08.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Gonzalez-Galvez G, Gron R, Halladin N, Haluzik M, Jermendy G, Kok A, Orsy P, Sabbah M, Sesti G, Silver R
|
|
|
2.
|
Stent thrombosis is not increased following percutaneous coronary intervention in patients with non-insulin dependent diabetes mellitus taking metformin. MedStar authors:
- Chen, Fang
- Lipinski, Michael J
- Pendyala, Lakshmana K
- Torguson, Rebecca
- Waksman, Ron
Citation: - Atherosclerosis. 235(2):295-8, 2014 Aug.
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
- Journal Article
- Observational Study
All authors: - Chen F, Lipinski MJ, Pendyala LK, Torguson R, Waksman R
|
|
|
3.
|
Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. MedStar authors:
Year: 2019
Citation: - Diabetes Technology & Therapeutics. 21(5):273-285, 2019 May.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Bailey TS, Bergenstal RM, Brazg RL, Calibra Study Group, Dreon DM, Frias JP, Johnson ML, Klonoff DC, Kruger DF, Levy BL, Naik RG, Peyrot M, Ramtoola S, Rosenstock J, Serusclat P, Shearer DM, Weinstock RS, Zraick V
|
|
|
4.
|
|
|
|
5.
|
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. MedStar authors:
Year: 2017
Citation: - The Lancet Diabetes & Endocrinology. 5(5):355-366, 2017 May
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Axelsen M, Bain SC, Cariou B, DeVries JH, Piletic M, Rose L, Rowe E
|
|
|
6.
|
|
|
|
7.
|
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. MedStar authors:
Year: 2018
Citation: - The Lancet Diabetes & Endocrinology. 6(4):275-286, 2018 04.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Andreassen C, Aroda VR, Lingvay I, Ludemann J, Navarria A, Pratley RE, SUSTAIN 7 investigators, Viljoen A
|
|
|
8.
|
PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. MedStar authors:
Year: 2019
Citation: - Diabetes Care. 42(9):1724-1732, 2019 09.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Altuntas Y, Aroda VR, Christiansen E, Haluzik M, Hertz CL, Jeppesen OK, Lalic NM, Morales Villegas EC, PIONEER 1 Investigators, Rosenstock J, Terauchi Y
|
|
|
9.
|
A Low-Fat Dietary Pattern and Diabetes: A Secondary Analysis From the Women's Health Initiative Dietary Modification Trial. MedStar authors:
Year: 2017
Citation: - Diabetes Care. 41(4):680-687, 2018 04.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Allison M, Aragaki AK, Hingle MD, Howard BV, Johnson KC, Manson JE, Prentice RL, Shadyab AH, Shikany JM, Snetselaar LG, Thomson CA, Tinker LF, Zaslavsky O
|
|
|
10.
|
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. MedStar authors:
Year: 2016
Citation: - Diabetes Care. 39(9):1579-86, 2016 Sep
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Diamant M, Fonseca V, LixiLan PoC Study Group, Perfetti R, Rosenstock J, Silvestre L, Souhami E, Zhou T
|
|
|
11.
|
|
|
|
12.
|
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW. MedStar authors:
Year: 2014
Citation: - Diabetes Care. 37(6):1706-11, 2014 Jun.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, Non-P.H.S.
All authors: - Banerji M, Bray GA, Buchanan TA, Clement SC, DeFronzo RA, Gastaldelli A, Henry RR, Kitabchi AE, Mudaliar S, Musi N, Ratner RE, Reaven PD, Schwenke DC, Stentz FB, Tripathy D
|
|
|
13.
|
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. MedStar authors:
Year: 2019
Citation: - Diabetes Care. 42(12):2262-2271, 2019 12.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Araki E, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, PIONEER 8 investigators, Tarp-Johansen MJ, Zinman B
|
|
|
14.
|
|
|
|
15.
|
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. MedStar authors:
Year: 2017
Citation: - Diabetes, Obesity & Metabolism. 19(10):1408-1415, 2017 Oct.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Bergenstal RM, Bonadonna RC, Kapitza C, LixiLan-L trial investigators, Niemoeller E, Puig-Domingo M, Souhami E, Stager W, Wysham C, Yu C
|
|
|
16.
|
Lifestyle, Glycosylated Hemoglobin A1c, and Survival Among Patients With Stable Ischemic Heart Disease and Diabetes. MedStar authors:
Year: 2019
Citation: - Journal of the American College of Cardiology. 73(16):2049-2058, 2019 04 30.
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
All authors: - Berman DS, Boden WE, COURAGE Trial Research Group, Hartigan PM, Kostuk WJ, Mancini GBJ, Maron DJ, Spertus JA, Teo KK, Weintraub WS
|
|
|
17.
|
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). MedStar authors:
Year: 2014
Citation: - Journal of Diabetes & its Complications. 28(3):386-92, 2014 May-Jun.
Institution: - MedStar Health Research Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Boka G, Hanefeld M, Min KW, Miossec P, Muehlen-Bartmer I, Ratner RE, Rosenstock J, Shamanna P, Zhou T
|
|
|
18.
|
An update on pharmacotherapies in diabetic dyslipidemia. [Review] MedStar authors:
Year: 2019
Citation: - Progress in Cardiovascular Diseases. 62(4):334-341, 2019 Jul - Aug.
Institution: - MedStar Union Memorial Hospital
Medline publication type:
All authors: - Bandyopadhyay D, Blumenthal C, Deedwania P, Ghosh RK, Gupta M, Philip K, Tummala R, Ventura H
|
|
|
19.
|
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. MedStar authors:
Year: 2016
Citation: - Diabetes Care. 39(11):1972-1980, 2016 Nov
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Bellido D, Bergenstal RM, Gonzalez-Galvez G, Guo H, LixiLan-L Trial Investigators, Niemoeller E, Rosenstock J, Souhami E, Takami A, Unger J, Wysham C
|
|
|
20.
|
Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).[Erratum appears in Diabetes Obes Metab. 2016 Sep;18(9):952; PMID: 27546838] MedStar authors:
Year: 2016
Citation: - Diabetes, Obesity & Metabolism. 18(7):663-70, 2016 Jul
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Andersen TH, Aroda VR, Bailey TS, Cariou B, Kumar S, Leiter LA, Philis-Tsimikas A, Raskin P, Zacho J
|
|
|
21.
|
Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). MedStar authors:
- Fatemi, Omid
- Yuriditsky, Eugene
Citation: - American Journal of Cardiology. 114(8):1217-22, 2014 Oct 15.
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
- Comparative Study
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
All authors: - Basile J, Bigger T, Cushman W, Fatemi O, Goff D, Morgan T, Papademetriou V, Soliman EZ, Thomas A, Tsachris D, Tsioufis C, Yuriditsky E
|
|
|
22.
|
Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. [] MedStar authors:
Year: 2014
Citation: - Diabetes Care. 37(8):2317-25, 2014 Aug.
Institution: - MedStar Health Research Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Ahren B, Chow FC, Fonseca VA, Gross JL, Harmony 6 Study Group, Johnson SL, Leiter LA, Miller D, Ratner RE, Rosenstock J, Stewart MW, Yang F
|
|
|
23.
|
Arsenic exposure, arsenic metabolism, and incident diabetes in the strong heart study. MedStar authors:
- Howard, Barbara V
- Umans, Jason G
Citation: - Diabetes Care. 38(4):620-7, 2015 Apr.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
All authors: - Best LG, Francesconi KA, Goessler W, Gribble MO, Guallar E, Howard BV, Kuo CC, Lee E, Navas-Acien A, Umans JG
|
|
|
24.
|
Synergy to reduce emergency department visits for uncontrolled hyperglycemia. MedStar authors:
- Dubin, Jeffrey S
- Fokar, Ali
- Magee, Michelle F
- Nassar, Carine M
- Sharretts, John M
- Smith, Mark S
Citation: - Diabetes Educator. 39(3):354-64, 2013 May-Jun.
Institution:
- MedStar Diabetes Institute
- MedStar Health Research Institute
- MedStar Washington Hospital Center
Department:
- Emergency Medicine
- Medicine/Endocrinology
- MedStar Diabetes Institute
Medline publication type:
- Evaluation Studies
- Journal Article
- Research Support, Non-U.S. Gov't
All authors: - Copeland J, Dubin JS, Fokar A, Magee MF, Nassar CM, Sharretts JM, Smith MS
|
|
|
25.
|
|
|
|
26.
|
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. MedStar authors:
Year: 2018
Citation: - Diabetes Care. 41(2):258-266, 2018 02.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Ahmann AJ, Annett MP, Aroda VR, Capehorn M, Charpentier G, Dotta F, Henkel E, Holst AG, Lingvay I
|
|
|
27.
|
|
|
|
28.
|
Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. MedStar authors:
Year: 2020
Citation: - Diabetes Care. 43(5):940-947, 2020 05.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Butera NM, Camp AW, Cherrington A, Craig J, Fortmann SP, GRADE Research Group, Hollander PA, Krakoff J, Perez M, Phillips LS, Rasouli N, Sivitz WI, Tan MH, Tiktin M, Wexler DJ, Younes N
|
|
|
29.
|
Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. MedStar authors:
Year: 2019
Citation: - Diabetes Care. 42(11):2108-2116, 2019 11.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Blonde L, Del Prato S, Frias J, Henry R, Ji C, Niemoeller E, Rosenstock J, Shehadeh N, Souhami E
|
|
|
30.
|
Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History). MedStar authors:
Year: 2012
Citation: - The International Journal of Cardiovascular Imaging. 28(3):455-65, 2012 Mar.
Institution: - MedStar Health Research Institute
Medline publication type:
- Comparative Study
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - APPROACH study group, Brugaletta S, Garcia-Garcia HM, Garg S, Huang C, Kolatkar NS, Kravitz BG, Miller DM, Morocutti G, Nesto RW, Ratner RE, Serruys PW
|
|
|
31.
|
Neuropsychiatric safety with liraglutide 3.0mg for weight management: results from randomized controlled phase 2 and 3a trials. MedStar authors:
Year: 2017
Citation: - Diabetes, Obesity & Metabolism. 19(11):1529-1536, 2017 Nov.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Astrup A, Brett J, Cancino A, Kushner R, Lau DC, O'Neil PM, Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups, Wadden TA, Wilding JP
|
